Recent Advances of Dendritic Cells (DCs)-Based Immunotherapy for Malignant Gliomas
Authors:
- 1 September 2009
- journal article
- review article
- Published by SAGE Publications in Cell Transplantation
- Vol. 18 (9) , 977-983
Abstract
Immunotherapy is a new light of hope for the treatment of malignant gliomas. The brain is no longer believed to be an immunologically privileged organ. The major advantage of immunotherapy is the tumor-specific cytotoxic effect on the tumor cells with minimal side effects. Autologous dendritic cells (DCs)-based immunotherapy is a promising and feasible method. DCs are the most potent antigen-presenting cells (APCs). DCs prime T lymphocytes by epitopic major histocompatibility (MHC) class I and II for CD8 + cytotoxic T lymphocytes (CTLs) and CD4 + T helper cells, respectively. From the tissue specimen examination after DCs-based immunotherapy, CD8 + CTLs have replaced T regulatory cells (Tregs) as the major dominant tissue infiltrating lymphocytes (TILs). CD8 + CTLs play a key role in the tumor response, which may also be effective against cancer stem cells. DCs themselves also produce many cytokines including interferon-γ and interleukin (IL-2) to kill the tumor cells. From the preliminary better outcomes in the literature for malignant gliomas, DC-based immunotherapy may improve tumor response by increasing the survival rate and time. It is recommended that DC-based immunotherapy is applied as soon as possible with conjunctive radiotherapy and chemotherapy. Malignant gliomas have heterogeneity of tissue-associated antigens (TAAs). To find universal common antigens through different kinds of tumor culture may be the essential issue for tumor vaccine development in the future.Keywords
This publication has 59 references indexed in Scilit:
- Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma MultiformeClinical Cancer Research, 2008
- Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain gliomaBMC Neuroscience, 2008
- Enhanced antitumour immunity by combined use of temozolomide and TAT‐survivin pulsed dendritic cells in a murine gliomaImmunology, 2007
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor MicroenvironmentClinical Cancer Research, 2005
- Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccinesJournal of Neurosurgery, 2005
- Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II TrialClinical Cancer Research, 2005
- Induction of Antigen-Specific Immune Responses Against Malignant Brain Tumors by Intramuscular Injection of Sindbis DNA Encoding Gp100 and IL-18DNA and Cell Biology, 2005
- Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991Journal of Neurosurgery, 1998
- Relationship of lymphocyte invasion and survival of brain tumor patientsAnnals of Neurology, 1978